Business · 31/08/2022Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for THEROX Downstream System Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of THEROX Downstream System, a medical device, following a submission to the US Patent and Trademark Office (USPTO)
Original source language: Federal Register — Food and Drug AdministrationOpen original release →